Search

Your search keyword '"Pitisci, Angela"' showing total 12 results
Start Over Author "Pitisci, Angela" Publication Type Magazines
12 results on '"Pitisci, Angela"'

2. Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD

Author

Velardi, Enrico, Flamini, Sara, Galaverna, Federica, Boccieri, Emilia, Dolores De Luca, Carmen, Benini, Francesca, Quagliarella, Francesco, Rosichini, Marco, Catanoso, Marialuigia, Cardinale, Antonella, Velardi, Shirley, Volpe, Gabriele, Pitisci, Angela, Coccetti, Marianna, Carta, Roberto, Del Bufalo, Francesca, Bertaina, Valentina, Becilli, Marco, Pagliara, Daria, Algeri, Mattia, Merli, Pietro, and Locatelli, Franco

Published
2022
Full Text
View/download PDF

3. CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia

Author

Caruso, Simona, Quintarelli, Concetta, De Angelis, Biagio, Del Bufalo, Francesca, Ciccone, Roselia, Donsante, Samantha, Volpe, Gabriele, Manni, Simona, Guercio, Marika, Pezzella, Michele, Iaffaldano, Laura, Silvestris, Domenico Alessandro, Sinibaldi, Matilde, Di Cecca, Stefano, Pitisci, Angela, Velardi, Enrico, Merli, Pietro, Algeri, Mattia, Lodi, Mariachiara, Paganelli, Valeria, Serafini, Marta, Riminucci, Mara, and Locatelli, Franco

Published
2022
Full Text
View/download PDF

4. Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD

Author

Velardi, Enrico, Flamini, Sara, Galaverna, Federica, Boccieri, Emilia, Dolores De Luca, Carmen, Benini, Francesca, Quagliarella, Francesco, Rosichini, Marco, Catanoso, Marialuigia, Cardinale, Antonella, Velardi, Shirley, Volpe, Gabriele, Pitisci, Angela, Coccetti, Marianna, Carta, Roberto, Del Bufalo, Francesca, Bertaina, Valentina, Becilli, Marco, Pagliara, Daria, Algeri, Mattia, Merli, Pietro, and Locatelli, Franco

Published
2022
Full Text
View/download PDF

5. CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia

Author

Caruso, Simona, Quintarelli, Concetta, De Angelis, Biagio, Del Bufalo, Francesca, Ciccone, Roselia, Donsante, Samantha, Volpe, Gabriele, Manni, Simona, Guercio, Marika, Pezzella, Michele, Iaffaldano, Laura, Silvestris, Domenico Alessandro, Sinibaldi, Matilde, Di Cecca, Stefano, Pitisci, Angela, Velardi, Enrico, Merli, Pietro, Algeri, Mattia, Lodi, Mariachiara, Paganelli, Valeria, Serafini, Marta, Riminucci, Mara, and Locatelli, Franco

Published
2022
Full Text
View/download PDF

6. Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts

Author

Quintarelli, Concetta, Boffa, Iolanda, Sinibaldi, Matilde, Orlando, Domenico, Guercio, Marika, Di Cecca, Stefano, Caruso, Simona, Pitisci, Angela, Bertaina, Valentina, Del Bufalo, Francesca, Merli, Pietro, Algeri, Mattia, Galaverna, Federica, Vinti, Luciana, Li Pira, Giuseppina, De Angelis, Biagio, and Locatelli, Franco

Abstract

In view of the exciting results reported in patients with CD19+ malignancies given CAR T cells, it is expected that a continuously growing number of patients will be offered this treatment and, thus, will be exposed to gene-modified products. Since the techniques of gene manipulation are relatively new, some of the risks associated to CAR T therapy may be unpredictable.

Published
2018
Full Text
View/download PDF

7. Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts

Author

Quintarelli, Concetta, Boffa, Iolanda, Sinibaldi, Matilde, Orlando, Domenico, Guercio, Marika, Di Cecca, Stefano, Caruso, Simona, Pitisci, Angela, Bertaina, Valentina, Del Bufalo, Francesca, Merli, Pietro, Algeri, Mattia, Galaverna, Federica, Vinti, Luciana, Li Pira, Giuseppina, De Angelis, Biagio, and Locatelli, Franco

Abstract

Locatelli: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Honoraria; bluebird bio: Consultancy; Bellicum: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees.

Published
2018
Full Text
View/download PDF

8. CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells

Author

Quintarelli, Concetta, Sivori, Simona, Caruso, Simona, Carlomagno, Simona, Boffa, Iolanda, Orlando, Domenico, Guercio, Marika, Cembrola, Biancamaria, Pitisci, Angela, Di Cecca, Stefano, Li Pira, Giuseppina, Vinti, Luciana, De Angelis, Biagio, Moretta, Lorenzo, and Locatelli, Franco

Abstract

Locatelli: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; bluebird bio: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Honoraria; Bellicum: Consultancy, Membership on an entity's Board of Directors or advisory committees.

Published
2018
Full Text
View/download PDF

9. CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells

Author

Quintarelli, Concetta, Sivori, Simona, Caruso, Simona, Carlomagno, Simona, Boffa, Iolanda, Orlando, Domenico, Guercio, Marika, Cembrola, Biancamaria, Pitisci, Angela, Di Cecca, Stefano, Li Pira, Giuseppina, Vinti, Luciana, De Angelis, Biagio, Moretta, Lorenzo, and Locatelli, Franco

Abstract

Based on the clinical success observed in acute lymphoblastic leukemia (ALL) with chimeric antigen receptor engineered T (CAR T), we hypothesized that combining the specificity of a CAR with the innate allo-reactivity of KIR-mismatched NK cells might provide a powerful tool for adoptive cell therapy. The use of a third-party bank of CAR-NK cells offers the advantage of an immediate availability to be exploited in the allogenic setting and could be associated with a lower toxicity profile than CAR-T cells.

Published
2018
Full Text
View/download PDF

11. BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)

Author

Lucarelli, Barbarella, Merli, Pietro, Bertaina, Alice, Sinibaldi, Matilde, Gaspari, Stefania, Strocchio, Luisa, Pitisci, Angela, Li Pira, Giuseppina, Milano, Giuseppe Maria, Moseley, Annemarie, Quintarelli, Concetta, and Locatelli, Franco

Abstract

Moseley: Bellicum Pharmaceuticals: Employment, Equity Ownership.

Published
2015
Full Text
View/download PDF

12. BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)

Author

Lucarelli, Barbarella, Merli, Pietro, Bertaina, Alice, Sinibaldi, Matilde, Gaspari, Stefania, Strocchio, Luisa, Pitisci, Angela, Li Pira, Giuseppina, Milano, Giuseppe Maria, Moseley, Annemarie, Quintarelli, Concetta, and Locatelli, Franco

Abstract

Background:T-cell depleted haplo-HSCT is an established treatment for children with primary immune deficiencies (PID). However, children given this type of allograft are exposed to the risk of fatal events due to viral infections because of the prolonged impairment of adaptive immunity. We recently developed a novel method of selective T-cell depletion based on physical elimination of α/β T cells (ClinicalTrial.gov identifier: NCT01810120), which was shown to be safe and more effective than transplantation of positively-selected CD34+ cells for preventing life-threatening infections. However, we recorded some severe and even fatal viral infections, which prompted us to explore innovative approaches to accelerate the recovery of adaptive immunity. For this purpose, we designed an ongoing phase I/II trial aimed at testing the safety and the efficacy of post-transplant infusion of BPX-501 cells in children with malignant or non-malignant disorders (ClinicalTrials.gov identifier: NCT02065869). We report 3 cases of children with either severe combined immune deficiency (SCID) or Wiskott-Aldrich syndrome (WAS), who were enrolled in the dose escalation phase of the study and who cleared cytomegalovirus (CMV) or Adenovirus (AdV) infections likely due to the contribution of the BPX-501 cells.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results